1. Home
  2. BMRA vs XBIO Comparison

BMRA vs XBIO Comparison

Compare BMRA & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

HOLD

Current Price

$1.93

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.06

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMRA
XBIO
Founded
1971
N/A
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.9M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
BMRA
XBIO
Price
$1.93
$3.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.4K
12.4K
Earning Date
04-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,311,000.00
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.87
$1.90
52 Week High
$4.60
$13.93

Technical Indicators

Market Signals
Indicator
BMRA
XBIO
Relative Strength Index (RSI) 32.27 47.60
Support Level N/A $2.94
Resistance Level $2.23 $3.44
Average True Range (ATR) 0.13 0.16
MACD -0.04 -0.01
Stochastic Oscillator 5.99 23.68

Price Performance

Historical Comparison
BMRA
XBIO

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: